Upfront Treatment in Chronic Myeloid Leukemia (CML)

1 Views
administrator
administrator
07/08/23

The panelists, Jorge Cortes, MD; Kevin Kelly, MD, PhD; David Snyder, MD, FACP; Harry Erba, MD, PhD; and Javier Pinilla-Ibarz, MD, PhD, deliberate whether first generation or second generation tyrosine kinase inhibitors (TKIs) are more appropriate as upfront therapy when treating chronic myeloid leukemia (CML).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next